Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Saurabh Zanwar(Mayo Clinic), Doris K. Hansen(Moffitt Cancer Center), Hamza Hashmi(Medical University of South Carolina), Aimaz Afrough(The University of Texas Southwestern Medical Center), Surbhi Sidana(Centro de Investigación del Cáncer), Frederick L. Locke(University of Chicago), Danai Dima(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Shaji Kumar(Mayo Clinic in Arizona), Yi Lin(Mayo Clinic), Leyla Shune(University of Kansas Medical Center), Shambavi Richard(Icahn School of Medicine at Mount Sinai), Peter A. Forsberg(University of Colorado Denver), Omar Castañeda Puglianini(Moffitt Cancer Center), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Joseph P. McGuirk(University of Kansas Medical Center), Douglas W. Sborov(University of Utah), Gurbakhash Kaur(The University of Texas Southwestern Medical Center), Charlotte Wagner(Huntsman Cancer Institute), Krina K. Patel(Université Paris Cité), Ciara L. Freeman(Moffitt Cancer Center), Larry Anderson(The University of Texas Southwestern Medical Center), Oren Pasvolsky(Rabin Medical Center), Megan M. Herr(Roswell Park Comprehensive Cancer Center), Alex Lieberman-Cribbin(Icahn School of Medicine at Mount Sinai), Jack Khouri(Cleveland Clinic), James A. Davis(Medical University of South Carolina), Rebecca Gonzalez(Moffitt Cancer Center)
Journal of Hematology & Oncology
June 6, 2024
Cited by 46


Related Papers